In the current study, nanoplexes having silencer CD44 siRNA, which performs as a model therapeutic drug, have shown high knockdown (>90%) in different mammalian cell lines (melanoma cell line, MV3; and retinal pigment epithelial cell line, ARPE-19). Here, CD44 is linked to melanoma.